Paper · 27870574
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L and 26 others. J Clin Oncol, 2017. Cited by 354 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Papers, record 27870574. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27870574
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Phenylurea Compounds | Major topic |
| Pyrimidines | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Hyperphosphatemia | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA022453 | NCI NIH HHS | United States | P30CA022453 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer | Background | ClinicalTrials.gov | |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 28,273,431 | Errata. | https://conductscience.org/library/papers/28273431 | PubMed |
| Erratum in | 30,695,652 | Errata. | https://conductscience.org/library/papers/30695652 | PubMed |
| Comment in | 27,918,716 | Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. | https://conductscience.org/library/papers/27918716 | PubMed |
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24,122,810 | Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. | Hepatology | 2014 | https://conductscience.org/library/papers/24122810 | PubMed |
| 2 | 18,552,176 | Drug-sensitive FGFR2 mutations in endometrial carcinoma. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18552176 | PubMed |
| 3 | 26,488,003 | Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. | Ann Transl Med | 2015 | https://conductscience.org/library/papers/26488003 | PubMed |
| 4 | 26,224,133 | Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. | Cancer Metastasis Rev | 2015 | https://conductscience.org/library/papers/26224133 | PubMed |
| 5 | 23,175,443 | Oncogenic FGFR3 gene fusions in bladder cancer. | Hum Mol Genet | 2013 | https://conductscience.org/library/papers/23175443 | PubMed |
| 6 | 9,331,099 | Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. | Cancer Res | 1997 | https://conductscience.org/library/papers/9331099 | PubMed |
| 7 | 19,515,808 | FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. | Am J Physiol Renal Physiol | 2009 | https://conductscience.org/library/papers/19515808 | PubMed |
| 8 | 23,002,168 | FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. | Cancer Discov | 2012 | https://conductscience.org/library/papers/23002168 | PubMed |
| 9 | 10,655,437 | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10655437 | PubMed |
| 10 | 24,174,329 | A genomics-based classification of human lung tumors. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24174329 | PubMed |
1 to 10 of 33
See all 33 referencesCited by241
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 354 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,713,707 | Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer. | J Pathol | 2026 | https://conductscience.org/library/papers/42713707 | PubMed |
| 42,633,326 | Advances in FGF/FGFR Signaling: Implications for Disease and Therapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42633326 | PubMed |
| 42,589,248 | Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589248 | PubMed |
| 42,489,892 | 7-azaindole as privileged scaffold: Advances in drug design and structural modification. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42489892 | PubMed |
| 42,146,765 | Research on Targeted Therapy for Malignant Tumors of the Biliary Tract. | Onco Targets Ther | 2026 | https://conductscience.org/library/papers/42146765 | PubMed |
| 42,058,998 | FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42058998 | PubMed |
| 41,998,829 | FGFR1 Promotes Malignant Progression in Lung Squamous Cell Carcinoma Through Activation of Wnt/β-Catenin Signaling. | Cancer Med | 2026 | https://conductscience.org/library/papers/41998829 | PubMed |
| 41,850,040 | Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301. | ESMO Open | 2026 | https://conductscience.org/library/papers/41850040 | PubMed |
| 41,804,750 | Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/41804750 | PubMed |
| 41,704,746 | Macrophage-Mediated Cellular Communication Networks in Lung Squamous Cell Carcinoma and Adenocarcinoma Revealed by Single-Cell Sequencing. | Mediators Inflamm | 2026 | https://conductscience.org/library/papers/41704746 | PubMed |
1 to 10 of 241
See all 241 cited byGenes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGF23 | 8,074 | PubTator's text mining | https://conductscience.org/library/genes/8074 | NCBI Gene |
| FGFR1 | 2,260 | PubTator's text mining | https://conductscience.org/library/genes/2260 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| FGFR4 | 2,264 | PubTator's text mining | https://conductscience.org/library/genes/2264 | NCBI Gene |
| KRAS | 3,845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5,609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| SLC17A5 | 26,503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| SPATA2 | 9,825 | PubTator's text mining | https://conductscience.org/library/genes/9825 | NCBI Gene |
| TXK | 7,294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27870574
GET https://conductscience.org/api/papers/v1/27870574/authors?page=2